GLP-1 Agonist Weight Loss Drugs May Cause Female Anorgasmia Through Reduced Blood Flow and Brain Signaling Changes

What the researchers found

A female patient developed anorgasmia following initiation of a GLP-1 receptor agonist. The authors propose several mechanisms: the most likely being GLP-1 agonist-induced vasoconstriction of smooth muscle, which reduces oxygen delivery and blood flow to the genitals, hindering genital engorgement, arousal, and the smooth muscle contractions essential for orgasm.

Additional proposed mechanisms involve GLP-1 receptor modulation in the hypothalamus, which may decrease dopamine and norepinephrine signaling — neurotransmitters crucial for motivation, pleasure, and orgasm — and disrupt pathways involved in sexual desire and arousal.

Why it matters

Tens of millions of people worldwide are now taking GLP-1 receptor agonists for weight loss and diabetes. Sexual side effects are rarely discussed, rarely screened for, and may be significantly underreported due to patient embarrassment or lack of awareness. If GLP-1 agonists commonly impair sexual function, this would affect quality of life for a massive patient population and should factor into prescribing decisions and informed consent.

How the study worked

This is a clinical case report with chart review of a single patient who developed anorgasmia after starting a GLP-1 agonist. A Doctor of Pharmacy was consulted to explore possible pharmacological mechanisms by which GLP-1 agonists could affect sexual function.

What this study cannot tell us

This is a single case report (n=1), the lowest level of clinical evidence. Causation cannot be established — the anorgasmia could be related to weight loss itself, psychological factors, hormonal changes, or other medications. The proposed mechanisms are theoretical and have not been experimentally validated. No specific GLP-1 agonist or dose is identified in the abstract. The prevalence of this side effect is entirely unknown.

How to read the evidence

This is a single case report with theoretical mechanistic discussion — the lowest tier of clinical evidence. It raises an important hypothesis but cannot establish prevalence, causation, or dose-response relationships.

When this study was published

Published in 2025, this is one of the first reports to specifically address sexual dysfunction as a side effect of GLP-1 agonists, making it timely given the explosive growth in prescriptions for these peptide drugs.

The bigger picture

This case report opens a new line of inquiry into the side effect profile of GLP-1 receptor agonists. As these peptide drugs become some of the most prescribed medications globally, understanding their full range of effects — including on sexual function — is critical. The proposed mechanisms (vascular and neurochemical) are biologically plausible and consistent with known GLP-1 receptor distribution in the hypothalamus. This could prompt larger pharmacovigilance studies and potentially influence drug labeling.

Questions still open

• How common is sexual dysfunction among the millions of patients taking GLP-1 receptor agonists, and is it being systematically underreported?
• Does the sexual side effect resolve after discontinuing the GLP-1 agonist, and if so, how quickly?
• Do different GLP-1 agonists (semaglutide vs. liraglutide vs. tirzepatide) carry different risks for sexual dysfunction based on their receptor selectivity profiles?

Common questions

Read the original research

Anorgasmia following initiation of GLP-1 agonist.

Sexual medicine, 13(3), qfaf047

Citation

Visvabharathy, Vidya; MacPhedran, Sally; Shupp, Katie; King, Benjamin. (2025). Anorgasmia following initiation of GLP-1 agonist.. Sexual medicine, 13(3), qfaf047. https://doi.org/10.1093/sexmed/qfaf047